PI
ITCI

PEAK6 Investments’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

PEAK6 Investments’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-33,900
Closed -$2.35M – 4474
2024
Q1 		$2.35M Buy
33,900
+12,000
+55% +$825K 0.01% 1301
2023
Q4 		$1.57M Buy
21,900
+100
+0.5% +$5.75K 0.01% 1723
2023
Q3 		$1.14M Buy
+21,800
New +$1.27M 0.01% 1738

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PEAK6 Investments's ITCI Position: Q3 2024 in Review

PEAK6 Investments held its Intra-Cellular Therapies Inc. (ITCI) position steady in Q3 2024 at 4,049 shares worth $296K. The position accounts for ﹤0.01% of the portfolio, ranked #2603.

PEAK6 Investments first reported a position in ITCI in Q2 2024 and has held it in 2 quarters since. 355 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

  • PEAK6 Investments held 4,049 shares of Intra-Cellular Therapies Inc. worth $296K as of Q3 2024.
  • PEAK6 Investments left its Intra-Cellular Therapies Inc. share count unchanged in Q3 2024.
  • Intra-Cellular Therapies Inc. made up ﹤0.01% of PEAK6 Investments's portfolio in Q3 2024, its #2603 holding.
  • PEAK6 Investments first reported a position in Intra-Cellular Therapies Inc. in Q2 2024 and has held it in 2 quarters since.
  • 355 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.